These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 26084729)

  • 1. Testing for treatment-biomarker interaction based on local partial-likelihood.
    Liu Y; Jiang W; Chen BE
    Stat Med; 2015 Nov; 34(27):3516-30. PubMed ID: 26084729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonparametric tests for stratum effects in the Cox model.
    Sun J; Yang I
    Lifetime Data Anal; 2000 Dec; 6(4):321-30. PubMed ID: 11190602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Simulation Study Comparing Different Statistical Approaches for the Identification of Predictive Biomarkers.
    Haller B; Ulm K; Hapfelmeier A
    Comput Math Methods Med; 2019; 2019():7037230. PubMed ID: 31312252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A visualization method measuring the performance of biomarkers for guiding treatment decisions.
    Yang H; Tang R; Hale M; Huang J
    Pharm Stat; 2016; 15(2):152-64. PubMed ID: 26632104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the Optimal Personalized Treatment Strategy Based on Selected Variables to Prolong Survival via Random Survival Forest with Weighted Bootstrap.
    Shen J; Wang L; Daignault S; Spratt DE; Morgan TM; Taylor JMG
    J Biopharm Stat; 2018; 28(2):362-381. PubMed ID: 28934002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of companion diagnostic device measurement performance on clinical validation of personalized medicine.
    Li M; Yu T; Hu YF
    Stat Med; 2015 Jun; 34(14):2222-34. PubMed ID: 25779099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine.
    Belhechmi S; Le Teuff G; De Bin R; Rotolo F; Michiels S
    BMC Bioinformatics; 2023 Mar; 24(1):96. PubMed ID: 36927444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying cut points for biomarker defined subset effects in clinical trials with survival endpoints.
    He P
    Contemp Clin Trials; 2014 Jul; 38(2):333-7. PubMed ID: 24948401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A likelihood and resampling based approach to dichotomizing a continuous biomarker in medical research.
    Su M; Fang L; Su Z
    J Biopharm Stat; 2013 May; 23(3):637-47. PubMed ID: 23611200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polynomial spline estimation and inference of proportional hazards regression models with flexible relative risk form.
    Huang JZ; Liu L
    Biometrics; 2006 Sep; 62(3):793-802. PubMed ID: 16984322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of biomarker-by-treatment interactions in randomized clinical trials with survival outcomes and high-dimensional spaces.
    Ternès N; Rotolo F; Heinze G; Michiels S
    Biom J; 2017 Jul; 59(4):685-701. PubMed ID: 27862181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials.
    Royston P; Sauerbrei W
    Stat Med; 2004 Aug; 23(16):2509-25. PubMed ID: 15287081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating trial and treatment heterogeneity in an individual patient data meta-analysis of survival data by means of the penalized maximum likelihood approach.
    Rondeau V; Michiels S; Liquet B; Pignon JP
    Stat Med; 2008 May; 27(11):1894-910. PubMed ID: 18069745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empirical likelihood for cumulative hazard ratio estimation with covariate adjustment.
    Dong B; Matthews DE
    Biometrics; 2012 Jun; 68(2):408-18. PubMed ID: 22059527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Joint estimation of time-dependent and non-linear effects of continuous covariates on survival.
    Abrahamowicz M; MacKenzie TA
    Stat Med; 2007 Jan; 26(2):392-408. PubMed ID: 16479552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mixed integer programming for multi-biomarker panel identification by distinguishing malignant from benign colorectal tumors.
    Zou M; Zhang PJ; Wen XY; Chen L; Tian YP; Wang Y
    Methods; 2015 Jul; 83():3-17. PubMed ID: 25980368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation and inference for the causal effect of receiving treatment on a multinomial outcome.
    Cheng J
    Biometrics; 2009 Mar; 65(1):96-103. PubMed ID: 18373714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variance estimation of a survival function for interval-censored survival data.
    Sun J
    Stat Med; 2001 Apr; 20(8):1249-57. PubMed ID: 11304740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcome.
    Graziani R; Guindani M; Thall PF
    Biometrics; 2015 Mar; 71(1):188-197. PubMed ID: 25319212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
    Morita S; Yamamoto H; Sugitani Y
    Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.